Real-Life Evidence on Stroke Prevention in SPAF

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

NCT02042534 ·Status: COMPLETED ·Phase: PHASE2

Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention

NCT02273700 ·Status: COMPLETED

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study

NCT02784717 ·Status: COMPLETED

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

NCT03684564 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

NCT03887780 ·Status: COMPLETED

Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

NCT03749057 ·Status: COMPLETED ·Phase: PHASE4

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation

NCT03746301 ·Status: COMPLETED

Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation

NCT02147444 ·Status: UNKNOWN

New Oral Anticoagulants (NOAC) in Stroke Patients

NCT03826927 ·Status: COMPLETED

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

NCT02387229 ·Status: TERMINATED ·Phase: PHASE3

RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke

NCT02129920 ·Status: UNKNOWN

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

NCT05262322 ·Status: COMPLETED

Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

NCT03021928 ·Status: UNKNOWN ·Phase: PHASE3

TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation

NCT02961348 ·Status: COMPLETED ·Phase: NA

Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

NCT03772457 ·Status: UNKNOWN

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

NCT03192215 ·Status: TERMINATED ·Phase: PHASE3

Xarelto [SPAF] Post-marketing Surveillance in Japan

NCT01582737 ·Status: COMPLETED

Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial

NCT02818868 ·Status: COMPLETED

Novel Oral Anticoagulants in Stroke Patients

NCT02353585 ·Status: COMPLETED

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

NCT02640222 ·Status: COMPLETED

Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients(REPAIRS)

NCT02484027 ·Status: UNKNOWN ·Phase: PHASE4

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046 ·Status: RECRUITING ·Phase: PHASE3

Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

NCT03062319 ·Status: TERMINATED ·Phase: PHASE4

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

NCT06057467 ·Status: RECRUITING ·Phase: NA

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803 ·Status: COMPLETED ·Phase: PHASE2